TrialThe Lancet. Infectious diseases2015

Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial.

Christopher Koh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.